Abstract
Copper catalyzed azide-alkyne cycloaddition (CuAAC) chemistry is reported for the construction of previously unknown 5-(1H-1,2,3-triazol-1-yl)-4,5′- bithiazoles from 2-bromo-1-(thiazol-5-yl)ethanones. These novel triazolobithiazoles are shown to have cystic fibrosis (CF) corrector activity and, compared to the benchmark bithiazole CF corrector corr-4a, improved log P values (4.5 vs 5.96).
Original language | English (US) |
---|---|
Pages (from-to) | 5247-5253 |
Number of pages | 7 |
Journal | Bioorganic and Medicinal Chemistry |
Volume | 20 |
Issue number | 17 |
DOIs | |
State | Published - Sep 1 2012 |
Keywords
- CF corrector
- CuAAC
- Cystic fibrosis
- Triazolobithiazole
ASJC Scopus subject areas
- Pharmaceutical Science
- Drug Discovery
- Organic Chemistry
- Molecular Medicine
- Molecular Biology
- Clinical Biochemistry
- Biochemistry